Oruka Therapeutics: Pay

Oruka Therapeutics paid its 3 named executives $8.0M in total in FY2025 (Dec). CEO Lawrence Klein was paid $3.4M of that.

Pay$100 in the stock at the end of FY23 → $276
CEO pay is from each proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Pay of each named executive

Lawrence KleinChief Executive Officer
FY2025 (Dec)
FY2024 (Dec)
2 years
Joana GoncalvesChief Medical Officer
FY2025 (Dec)
FY2024 (Dec)
2 years
Paul QuinlanGeneral Counsel
FY2025 (Dec)
1 year

CEO pay against the pay peers

In FY2025 (Dec), the median CEO pay of the 4 peers with pay on file was $7.6M. The CEO of Oruka Therapeutics was paid $3.4M, 56% below the median.

  1. 1Kymera Therapeutics
  2. 2Structure Therapeutics
  3. 3Spyre Therapeutics
  4. 4Celldex Therapeutics
  5. 5Oruka Therapeutics
  6. 6Apogee TherapeuticsNot disclosed
  7. 7Astria TherapeuticsNot disclosed
  8. 8CARGO TherapeuticsNot disclosed
  9. 9Cabaletta BioNot disclosed
  10. 10Contineum TherapeuticsNot disclosed
  11. 11Entrada TherapeuticsNot disclosed
  12. 12Janux TherapeuticsNot disclosed
  13. 13Kyverna TherapeuticsNot disclosed
  14. 14Lexeo TherapeuticsNot disclosed
  15. 15Longboard PharmaceuticalsNot disclosed
  16. 16Lyell ImmunopharmaNot disclosed
  17. 17Pliant TherapeuticsNot disclosed
  18. 18Prime MedicineNot disclosed
  19. 19Third Harmonic BioNot disclosed

Pay of each named executive comes from the Summary Compensation Table of each proxy statement. Realized pay adds the value of options used and stock that vested. CEO pay of each peer comes from its own Pay versus Performance table.